WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Executive Summary TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...
WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...
Potential TScan Therapeutics, Inc. (NASDAQ:TCRX) shareholders may wish to note that the Chairman of the Board, Timothy Barberich, recently bought US$142k worth of stock, paying US$4.89 for each share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results